Syneron spikes on Q2 earnings that beat Street estimates

Shares of Syneron Medical Ltd. (Nasdaq:ELOS) were up 5% this morning after the company reported before the opening second-quarter earnings and revenue that topped analysts’ estimates.

For the three months ended June 30, the Israeli medical aesthetic devices maker said it earned $11 million, or $0.40 per share, on revenue of $38.2 million compared with earnings of $10.3 million, or $0.37 per share, on revenue of $37.5 million in the prior year quarter.

Analysts polled by Thomson First Call had expected earnings per share of $0.32 on revenue of $37.1 million.

International sales were up 17% over the same period last year.

By late morning, Syneron was at $16.61, up $0.83 from Wednesday’s close. The stock has ranged between $13.35 and $25.50 during the past 52 weeks.

For detailed price information and news stories on Syneron, click ELOS.

About the Author
Contributing author Mary Ann Azevedo has more than 13 years of writing and editing experience that includes coverage of a broad range of companies. Read More

Rate This Article:
(click a star)

Enter comment:

 Free registration required